Medscape InDiscussion: CAR T-Cell Therapy
Medscape
5.0from 7 ratings
- 6
- Episodes
- 7
- Ratings
- 2023
- First episode
About Medscape InDiscussion: CAR T-Cell Therapy
Listen to Medscape InDiscussion: CAR T-Cell Therapy, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987065). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
- Publisher
- Medscape
- Category
- health & fitness · science
- Language
- en
- Explicit
- No
- First episode
- 11 May 2023
- Latest episode
- 12 Sept 2023
Latest episodes
6 episodes in the feed.
12 Sept 2023
The Future of CAR T-cell Therapy
Join Drs Amelia Langston and Frederick Locke as they discuss the future of CAR T-cell therapy research and treatment. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987070). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Cancer Immunotherapy With Chimeric Antigen Receptor (CAR) T Cells https://emedicine.medscape.com/article/2500108-overview Adoptive Cell Therapy https://www.cancer.gov/publications/dictionaries/cancer-terms/def/adoptive-cell-therapy Graft Versus Host Disease (GVHD) https://emedicine.medscape.com/article/429037-overview Multiple Myeloma https://emedicine.medscape.com/article/204369-overview BCMA in Multiple Myeloma-A Promising Key to Therapy https://pubmed.ncbi.nlm.nih.gov/34575199/ Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on "Off-the-shelf" T Cell Therapy Using iPSC Technology and Gene Editing https://pubmed.ncbi.nlm.nih.gov/35053386/ Cytokine Release Syndrome https://emedicine.medscape.com/article/2500111-overview Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/34466048/ Preclinical and Clinical Studies of CAR-NK-cell Therapies for Malignancies https://pubmed.ncbi.nlm.nih.gov/36353643/ How I Treat Cytopenias After CAR T-cell Therapy https://pubmed.ncbi.nlm.nih.gov/36800563/ T-cell Receptor-based Therapy: An Innovative Therapeutic Approach for Solid Tumors https://pubmed.ncbi.nlm.nih.gov/34193217/ Biochemistry, HLA Antigens https://www.ncbi.nlm.nih.gov/books/NBK546662/ CAR T-cell Cancer Therapy Targeting Surface Cancer/Testis Antigens https://pubmed.ncbi.nlm.nih.gov/32983080/ Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges https://pubmed.ncbi.nlm.nih.gov/36077696/ Axicabtagene Ciloleucel CAR T-cell Therapy in Refractory Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/29226797/ Axicabtagene Ciloleucel as Second-line Therapy for Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/34891224/
10 Aug 2023
CAR T-Cell Therapy for Multiple Myeloma
Join Drs Amelia Langston and Jonathan L. Kaufman, MD, as they discuss current CAR–T cell for B-cell lymphomas as leading researchers and practitioners in the field. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987069). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Cancer Immunotherapy With Chimeric Antigen Receptor (CAR) T Cells https://emedicine.medscape.com/article/2500108-overview Multiple Myeloma https://emedicine.medscape.com/article/204369-overview CD19 https://www.ncbi.nlm.nih.gov/gene/930 BCMA in Multiple Myeloma - A Promising Key to Therapy https://pubmed.ncbi.nlm.nih.gov/34575199/ Histology, Plasma Cells https://www.ncbi.nlm.nih.gov/books/NBK556082/ Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/33626253/ Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b/2 Open-Label Study https://pubmed.ncbi.nlm.nih.gov/34175021/ Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? [Internet] https://www.ncbi.nlm.nih.gov/books/NBK137763/ Ide-Cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/36762851/ Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies https://pubmed.ncbi.nlm.nih.gov/35877215/ Bispecific Targeting of CD20 and CD19 Increases Polyfunctionality of Chimeric Antigen Receptor T-Cell Products in B-Cell Malignancies https://pubmed.ncbi.nlm.nih.gov/35597752/ Bridging Chemotherapy: Multiple Myeloma https://www.ncbi.nlm.nih.gov/books/NBK584176/ Autologous Bone Marrow Transplant https://www.cancer.gov/publications/dictionaries/cancer-terms/def/autologous-bone-marrow-transplant Myelodysplastic Syndrome (MDS) https://emedicine.medscape.com/article/207347-overview GPRC5D-Targeted CAR T Cells for Myeloma https://pubmed.ncbi.nlm.nih.gov/36170501/ Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/36507686/ Elotuzumab: The First Approved Monoclonal Antibody for Multiple Myeloma Treatment https://pubmed.ncbi.nlm.nih.gov/27493709/ Natural Killer Cells in the Malignant Niche of Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/35087536/
11 Jul 2023
CAR T-Cell Therapy for B-Cell Lymphomas
Join Drs Amelia Langston and Loretta Nastoupil as they discuss current CAR T-cell therapy for B-cell lymphomas as leading researchers and practitioners in the field. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987068). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Axicabtagene Ciloleucel CAR T-cell Therapy in Refractory Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/29226797/ Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/30501490/ Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B-cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study https://pubmed.ncbi.nlm.nih.gov/32888407/ Axicabtagene Ciloleucel as Second-line Therapy for Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/34891224/ Lisocabtagene Maraleucel Versus Standard of Care With Salvage Chemotherapy Followed by Autologous Stem Cell Transplantation as Second-line Treatment in Patients With Relapsed or Refractory Large B-cell Lymphoma (TRANSFORM): Results From an Interim Analysis of an Open-label, Randomised, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/35717989/ Second-line Tisagenlecleucel or Standard Care in Aggressive B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/34904798/ KTE-X19 CAR T-cell Therapy in Relapsed or Refractory Mantle-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/32242358/ Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5): A Single-arm, Multicentre, Phase 2 Trial https://pubmed.ncbi.nlm.nih.gov/34895487/ Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23) https://clinicaltrials.gov/ct2/show/NCT05605899 Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122857/
13 Jun 2023
CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia
Join Drs Amelia Langston and Bijal Shah as they discuss CAR T-cell therapy for B-cell acute lymphoblastic leukemia, including clinical trials and real-world experience from their centers. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987067). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Cancer Immunotherapy With Chimeric Antigen Receptor (CAR) T Cells https://emedicine.medscape.com/article/2500108-overview Acute Lymphoblastic Leukemia (ALL) Treatment & Management https://emedicine.medscape.com/article/207631-treatment#d15 Non-Hodgkin Lymphoma (NHL) https://emedicine.medscape.com/article/203399-overview CD19 https://www.ncbi.nlm.nih.gov/gene/930 Tisagenlecleucel https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tisagenlecleucel Tisagenlecleucel in Children and Young Adults With B-Cell Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/29385370/ Clinical Significance and Management of MRD in Adults With Acute Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/32903253/ Blinatumomab (Rx) https://reference.medscape.com/drug/blincyto-blinatumomab-999984#10 FDA Approves Inotuzumab for Adults With B-Cell Acute Lymphoblastic Leukemia https://www.cancer.gov/news-events/cancer-currents-blog/2017/fda-inotuzumab-leukemia Immune Effector Cell Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor-T Cell Therapy https://pubmed.ncbi.nlm.nih.gov/36081506/ Cytokine Release Syndrome https://emedicine.medscape.com/article/2500111-overview Systemic Inflammatory Response Syndrome https://www.ncbi.nlm.nih.gov/books/NBK547669/ CD28 https://www.ncbi.nlm.nih.gov/gene/940 Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) (ROCKET) https://clinicaltrials.gov/ct2/show/NCT02535364 KTE-X19 for Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukaemia: Phase 2 Results of the Single-Arm, Open-label, Multicentre ZUMA-3 Study https://pubmed.ncbi.nlm.nih.gov/34097852/ CAR T-Cell Therapy Approved for Some Children and Young Adults With Leukemia https://www.cancer.gov/news-events/cancer-currents-blog/2017/tisagenlecleucel-fda-childhood-leukemia Allogeneic Stem Cell Transplant https://www.cancer.gov/publications/dictionaries/cancer-terms/def/allogeneic-stem-cell-transplant clonoSEQ Assay https://ous.clonoseq.com/for-clinicians/how-clonoseq-works/ Management of Hypogammaglobulinaemia and B-Cell Aplasia https://www.ncbi.nlm.nih.gov/books/NBK584138/ Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse After Tisagenlecleucel in Children and Young Adults With Acute Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/35019853/ Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial https://pubmed.ncbi.nlm.nih.gov/36399695/ Therapeutic Targeting of Mutated p53 in Acute Lymphoblastic Leukemia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939537/ MLL-Rearranged Acute Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/32350732/ Liposomal Vincristine for Relapsed or Refractory Ph-Negative Acute Lymphoblastic Leukemia: A Review of Literature https://pubmed.ncbi.nlm.nih.gov/24490021/ Consolidation Therapy With Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients With B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results From the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial https://ashpublications.org/blood/article/140/Supplement%202/LBA-1/493429/Consolidation-Therapy-with-Blinatumomab-Improves
11 May 2023
Monitoring and Management of CAR T-Cell Therapy Complications
Join Drs Amelia Langston and Jean Koff as they discuss the monitoring and management of complications before, during, and after CAR T therapy. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987066). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Cancer Immunotherapy With Chimeric Antigen Receptor (CAR) T Cells https://emedicine.medscape.com/article/2500108-overview Cytokine Release Syndrome https://emedicine.medscape.com/article/2500111-overview Immune Effector Cell Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor-T Cell Therapy https://pubmed.ncbi.nlm.nih.gov/36081506/ On-target and Off-target-based Toxicologic Effects https://pubmed.ncbi.nlm.nih.gov/23085982/ Cytokine https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cytokine Tocilizumab (Rx) https://reference.medscape.com/drug/actemra-tocilizumab-999419 CARTOX 10 Point Neurological Assessment https://reference.medscape.com/viewarticle/886616_5 Levetiracetam https://www.ncbi.nlm.nih.gov/books/NBK499890/ Cytopenia After CAR-T Cell Therapy-A Brief Review of a Complex Problem https://pubmed.ncbi.nlm.nih.gov/35326654/ Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome https://pubmed.ncbi.nlm.nih.gov/36906275/ Management of Hypogammaglobulinaemia and B-cell Aplasia https://www.ncbi.nlm.nih.gov/books/NBK584138/ Rituximab (Rx) https://reference.medscape.com/drug/rituxan-truxima-rituximab-342243 Bispecific Targeting of CD20 and CD19 Increases Polyfunctionality of Chimeric Antigen Receptor T-cell Products in B-cell Malignancies https://pubmed.ncbi.nlm.nih.gov/35597752/ Mantle Cell Lymphoma https://www.ncbi.nlm.nih.gov/books/NBK536985/ Chimeric Antigen Receptor (CAR) T-cell Treatment for Mantle Cell Lymphoma (MCL) https://pubmed.ncbi.nlm.nih.gov/35237395/ Apheresis https://www.cancer.gov/publications/dictionaries/cancer-terms/def/apheresis
11 May 2023
When Is CAR T-Cell Therapy the Answer?
Drs Amelia Langston and Melody Smith provide an overview of CAR T-cell therapy, the products available, potential complications, and what's next in this rapidly advancing field. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987065). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Non-viral, Specifically Targeted CAR-T Cells Achieve High Safety and Efficacy in B-NHL https://pubmed.ncbi.nlm.nih.gov/36045296/ Cytokine Release Syndrome With Chimeric Antigen Receptor T Cell Therapy https://pubmed.ncbi.nlm.nih.gov/30586620/ Immune Effector Cell-Associated Neurotoxicity Syndrome After Chimeric Antigen Receptor T-Cell Therapy for Lymphoma: Predictive Biomarkers and Clinical Outcomes https://pubmed.ncbi.nlm.nih.gov/32750704/ A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/33670075/ CAR T-cell Therapy for B-Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/35012754/ Current State and Next-Generation CAR-T Cells in Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/35131139/ Rapid Manufacturing of Non-activated Potent CAR T Cells https://pubmed.ncbi.nlm.nih.gov/35190680/
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
- Apple Podcasts (US)
- 5.0 / 5
- 5 ratings
- Spotify
- 5.0 / 5
- 2 ratings
Contact Medscape InDiscussion: CAR T-Cell Therapy
- Guest appearances
- Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Medscape InDiscussion: CAR T-Cell Therapy?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show
Podcast research with Pod Engine